Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
This study aims to benchmark and analyze the process development and manufacturing costs across the biopharmaceutical drug development cycle and their contribution to overall research and development (R&D) costs. This was achieved with a biopharmaceutical drug development lifecycle cost model that captured the costs, durations, risks and interdependencies of the clinical, process development and manufacturing activities. The budgets needed for process development and manufacturing at each phase of development to ensure a market success each year were estimated. The impact of different clinical success rate profiles on the process development and manufacturing costs at each stage was investigated, with a particular focus on monoclonal antibodies. To ensure a market success each year with an overall clinical success rate (Phase I to approval) of ~12%, the model predicted that a biopharmaceutical company needs to allocate process development and manufacturing budgets in the order of ~$60 M for pre-clinical to Phase II material preparation and ~$70 M for Phase III to regulatory review material preparation. For lower overall clinical success rates of ~4%, which are more indicative of diseases such as Alzheimer's, these values increase to ~$190 M for early-phase and ~$140 Mfor late-phase material preparation; hence, the costs increase 2.5 fold. The costs for process development and manufacturing per market success were predicted to represent 13-17% of the R&D budget from pre-clinical trials to approval. The results of this quantitative structured cost study can be used to aid decision-making during portfolio management and budget planning procedures in biopharmaceutical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 6×
“For this study, the methodology from Paul et al.(1) was used to find the capitalized phase costs, assuming a cost of capital of 11%.”
BackgroundMethodInfluentialInnovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“The pharmaceutical industry has suffered from declining research and development (R&D) productivity and increasing costs over the past few decades.(1,2) The reported capitalized R&D cost to bring a new biopharmaceutical to market has risen from $1.”
BackgroundAlzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“The worstcase scenario used an overall success rate of 4% derived from using the industrial average phase transition probabilities for pre-clinical to Phase II stages whilst addressing the possibility that for some therapeutic areas, such as Alzheimer’s disease, the phase transition probability of Phase III could be e…”
Method
Cited by
Bioprocess Control: Current Progress and Future Perspectives
Rathore, A. S., Mishra, S., Nikita, S., & Priyanka, P. (2021) · Life · doi:10.3390/life11060557 · Cited by 141
“duction cost across biopharmaceutical product cycle along with their contribution in overall research and development (R & D) cost [27].”
BackgroundMahal, H., Branton, H., & Farid, S. S. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27774 · Cited by 71
“CCMC‐PD was taken to include all bulk process and formulation development as well as analytical effort for process characterization and validation studies and the technology transfer activities (Farid et al., 2020).”
BackgroundMethodSelf-citationWang, J., Chen, J., Studts, J., & Wang, G. (2023) · mAbs · doi:10.1080/19420862.2023.2220149 · Cited by 37
Metadata
- Authors
- Farid, S. S., Baron, M., Stamatis, C., Nie, W., & Coffman, J.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2020-01
- Volume
- 12
- Issue
- 1
- Pages
- 1754999-1754999
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W3028363053
- Cited by
- 81
- References
- 4
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D. https://app.cochat.ai/papers/10.1080/19420862.2020.1754999
- The paper
- Farid, S. S., Baron, M., Stamatis, C., Nie, W., & Coffman, J. (2020). Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D. mAbs. https://doi.org/10.1080/19420862.2020.1754999
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.